2. Signaling Pathways
  3. Epigenetics
  4. Epigenetic Reader Domain
  5. BRD9 Isoform
  6. BRD9 Degrader

BRD9 Degrader

BRD9 Degraders (15):

Cat. No. Product Name Effect Purity
  • HY-182766
    AMX-883
    		Degrader
    AMX-883 a selective and orally active BRD9 molecular glue degrader that drives differentiation in acute myeloid leukaemia. AMX-883 shows selectivity over all other bromodomain containing proteins and proteome wide. AMX-883 does not employ the commonly used E3 ligases (cereblon, VHL) but instead drives degradation via DCAF16 as a targeted glue. AMX-883 can be used for the study of acute myeloid leukaemia (AML).
  • HY-184210
    XYD224
    		Degrader
    XYD224 is a selective BRD9 PROTAC degrader with a DC50 of 7.3 nM. XYD224 inhibits the proliferation of acute myeloid leukemia cells. XYD224 suppresses tumor growth in xenograft models. XYD224 is applicable for the research of acute myeloid leukemia (AML).
  • HY-117690
    dBRD9
    		Degrader 99.75%
    dBRD9,a PROTAC, can selective degrades BRD9. dBRD9 improves the bromine domain binding profile and reduces the binding activity of the whole BET family.
  • HY-148739
    dBRD 9-A
    		Degrader 99.50%
    dBRD 9-A is a selective BRD9 PROTAC degrader. dBRD 9-A induces near complete BRD9 degradation dependent on E3 ubiquitin ligase CRBN and BRD9 bromodomain engagement, and drives loss of BRD9 chromatin binding genome-wide. dBRD 9-A downregulates oncogenic SS18-SSX-driven transcriptional programs, super enhancer-associated gene expression, and SS18-SSX1 super enhancer binding, and depletes GBAF complex members GLTSCR1/1L from SS18-SSX complexes. dBRD 9-A induces cell cycle arrest and increases apoptosis in synovial sarcoma cells. dBRD 9-A can be used for the research of synovial sarcoma.
  • HY-155361
    PROTAC BRD9 Degrader-7
    		Degrader 99.29%
    PROTAC BRD9 Degrader-7 is an orally active, selective BRD9 PROTAC degrader (DC50 = 1.02 nM). PROTAC BRD9 Degrader-7 mediates BRD9 degradation via the ubiquitin-proteasome system. PROTAC BRD9 Degrader-7 exhibits proliferation inhibitory activity in the MV4-11 cells. PROTAC BRD9 Degrader-7 can be used in the research of acute myeloid leukemia and other related malignancies.
  • HY-145403
    PROTAC BRD9 Degrader-4
    		Degrader 99.06%
    PROTAC BRD9 Degrader-4 is a BRD9 bifunctional PROTAC degrader for researching cancer.
  • HY-178345
    ZZ7-23-022
    		Degrader
    ZZ7-23-022 (ZZ7) is a selective BRD9 molecule glue degrader. ZZ7-23-022 effectively degrades BRD9 in synovial sarcoma cells, but does not affect cardiomyocytes. ZZ7-23-022 can be used for the research of cancer.
  • HY-123616
    BI 7271
    		Degrader
    BI 7271 is a BRD9 ligand, which can be used for the synthesis of PROTACs, such as PROTAC BRD9 Degrader-7 (HY-155361).
  • HY-163809
    BRD9 Degrader-2
    		Degrader
    BRD9 Degrader-2 (Compound B11) is a BRD9 degrader (DC50 ≤1.25 nM; Dmax≥75%). BRD9 Degrader-2 can be used for research of cancers.
  • HY-181951
    PROTAC BRD9 Degrader-11
    		Degrader
    PROTAC BRD9 Degrader-11 is a VHL-based BRD9 PROTAC degraderwith an IC50 of 0.66 μM. PROTAC BRD9 Degrader-11 induces selective, proteasome-dependent degradation of BRD9 via the ubiquitin-proteasome system. PROTAC BRD9 Degrader-11 impairs cell viability, suppresses proliferation, and arrests growth of acute myeloid leukemia cells. PROTAC BRD9 Degrader-11 can be used for the research of acute myeloid leukemia.
  • HY-170314
    EA-89
    		Degrader
    EA-89 is a potent and selective BRD9 inhibitor with antitumor activity. EA-89 is a Ligand for Target Protein for PROTAC. EA-89 can be used to synthesize PROTAC QA-68 (HY-150797).
  • HY-163810
    BRD9 Degrader-3
    		Degrader
    BRD9 Degrader-3 (compound B20) is a BRD9 molecular glue, with a DC50 of <1.25 nM.
  • HY-162651
    PROTAC BRD9 Degrader-8
    		Degrader
    PROTAC BRD9 Degrader-8 is a selective, orally active BRD9 PROTAC degrader with a DC50 of 16 pM.\nPROTAC BRD9 Degrader-8 induces cell cycle arrest at the G1 phase and promotes apoptosis. PROTAC BRD9 Degrader-8 can be used for research on acute myeloid leukemia and diffuse large B-cell lymphoma.
  • HY-177729
    PROTAC BRD9 Degrader-9
    		Degrader
    PROTAC BRD9 Degrader-9 (Compound 16) is an efficient and selective targeting BRD9 PROTAC degrader. PROTAC BRD9 Degrader-9 does not cause significant cytotoxicity. PROTAC BRD9 Degrader-9 can be used for cancer research
  • HY-107446
    BI-7273 acid
    		Degrader
    BI-7273 acid, BI-7273 (HY-100351) derivative, is a BRD9 PROTAC ligand. BI-7273 acid can be conjugated with E3 ligase Ligand Thalidomide (HY-14658) and linker to synthesize BRD9 PROTAC degrader dBRD 9-A (HY-148739).